Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Exelixis Inc (EXEL)

Exelixis Inc (EXEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Exelixis Inc 1851 Harbor Bay Parkway Alameda CA 94502 USA

www.exelixis.com P: 650-837-7000 F: 650-837-8300

Description:

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the company's flagship molecule, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET.

Key Statistics

Overview:

Market Capitalization, $K 8,131,825
Enterprise Value, $K 7,868,835
Shares Outstanding, K 303,200
Annual Sales, $ 1,830 M
Annual Net Income, $ 207,770 K
Last Quarter Sales, $ 637,180 K
Last Quarter Net Income, $ 226,120 K
EBIT, $ 369,540 K
EBITDA, $ 395,260 K
60-Month Beta 0.54
% of Insider Shareholders 2.85%
% of Institutional Shareholders 85.27%
Float, K 294,559
% Float 97.15%
Short Volume Ratio 0.57

Growth:

1-Year Return 25.26%
3-Year Return 31.84%
5-Year Return 49.10%
5-Year Revenue Growth 114.35%
5-Year Earnings Growth -54.55%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.84 on 08/06/24
Next Earnings Date 11/06/24
Earnings Per Share ttm 1.14
EPS Growth vs. Prev Qtr 525.00%
EPS Growth vs. Prev Year 200.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

EXEL Ratios

Ratio
Price/Earnings ttm 24.21
Price/Earnings forward 17.83
Price/Earnings to Growth 0.60
Return-on-Equity % 15.54%
Return-on-Assets % 11.97%
Profit Margin % 11.35%
Debt/Equity 0.00
Price/Sales 4.30
Price/Cash Flow 35.67
Price/Book 3.70
Book Value/Share 7.43
Interest Coverage -1.47
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar